BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gastric Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Gastric Cancer\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03610711-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03610711)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: REACTION (Radia
 tion Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Ni
 volumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents
  After Targeted Systemic Radiation in Patients With Advanced Esophagogastr
 ic Cancer\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03610711
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208347-1972@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT04208347)
DESCRIPTION:Camrelizumab\, phase 2/3\, Gastric Cancer.\nStudy: Perioperativ
 e Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagoga
 stric Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04208347
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221748-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, Gastric Cancer.\nStudy: DV Comb
 ined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and 
 Gastroesophageal Junction Adenocarcinoma After Progression on First-line T
 herapy\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510010-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:S-1: Phase 2 readout est. (NCT06510010)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Perioperative Oxaliplat
 in With S-1 Combined H. Pylori Eradication in the Management of Locally Ad
 vanced Gastric Cancer\nEstimated primary completion: 28 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06510010
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03776487-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03776487)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: Nivolumab\, Ipili
 mumab and Chemoradiation in Treating Patients With Resectable Gastric Canc
 er\nEstimated primary completion: 30 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03776487
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03259867-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03259867)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combina
 tion of TATE and PD-1 Inhibitor in Liver Cancer\nEstimated primary complet
 ion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03259867
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combinat
 ion of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04140526
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05311189-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05311189)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Study of HLX10\
 , Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Re
 current/Metastatic Gastric Cancer\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0531
 1189
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238167-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06238167)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab P
 lus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients Wit
 h LA GC/GEJC\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06238167
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304258-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07304258)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: A Prospective\
 , Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Con
 version Therapy for Gastric Cancer With Peritoneal Metastasis With Positiv
 e Cytology Alone or PCI Score ≤10\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7304258
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439550-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06439550)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Adjuvant Treatm
 ent With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06439550
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391826-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07391826)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Megestrol Aceta
 te Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastro
 esophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serp
 lulimab Combined With SOX\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07391826
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238167-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06238167)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab Plus Chemo
 therapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/G
 EJC\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06238167
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304258-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT07304258)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Prospective\, Phase I
 I Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion T
 herapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytolog
 y Alone or PCI Score ≤10\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07304258
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555471-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06555471)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Single-arm\, Phase II
  Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in 
 Elderly Patients With Locally Advanced Gastric Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06555471
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730373-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06730373)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: First-line Treatment Wi
 th RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06730373
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730373-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06730373)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: First-lin
 e Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (
 RCTS2)\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06730373
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03161522-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03161522)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Chemotherapy W
 ith or Without Radiation or Surgery in Treating Participants With Oligomet
 astatic Esophageal or Gastric Cancer\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03161522
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555471-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06555471)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: A Single-arm\,
  Phase II Exploratory Study of Sintilimab in Combination With Chemoradioth
 erapy in Elderly Patients With Locally Advanced Gastric Cancer\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06555471
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939439-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06939439)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Using ctDNA to
  Guide Treatment Decisions for Stage III Gastric Cancer\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06939439
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519591-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:S-1: Phase 2 readout est. (NCT06519591)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Systemic Application of
  Cadonilimab\, LM-302\, and S-1 Combined With Intraperitoneal Infusion of 
 Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With 
 Peritoneal Metastasis\nEstimated primary completion: January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06519591
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257575-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07257575)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: A Randomized Co
 ntrolled Study of Serplulimab Combined With Chemotherapy for Locally Advan
 ced Gastric Adenocarcinoma\nEstimated primary completion: 31 January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07257575
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257575-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07257575)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Rand
 omized Controlled Study of Serplulimab Combined With Chemotherapy for Loca
 lly Advanced Gastric Adenocarcinoma\nEstimated primary completion: 31 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07257
 575
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04757363-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04757363)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Nivolu
 mab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative 
 Esophagogastric Cancer\nEstimated primary completion: February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04757363
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687357-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05687357)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab i
 n Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ
  Adenocarcinoma\nEstimated primary completion: 28 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05687357
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687357-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:S-1: Phase 2 readout est. (NCT05687357)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab in Combina
 tion With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocar
 cinoma\nEstimated primary completion: 28 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05687357
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab
  With or Without Bevacizumab\, in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06028737-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06028737)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Gastric Cancer.\nStudy: Tota
 l Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesop
 hageal Junction Cancer\nEstimated primary completion: 25 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06028737
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947291-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06947291)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Safety
  and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin
 -bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction
  Adenocarcinoma and Other Solid Tumors\nEstimated primary completion: 30 A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0694
 7291
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:S-1: Phase 2 readout est. (NCT06385873)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: RC48 Combined With Adeb
 relimab\, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gast
 ric Cancer\nEstimated primary completion: 1 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06385873)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: RC48 Comb
 ined With Adebrelimab\, Apatinib and S-1 as Neoadjuvant Therapy in Locally
  Advanced Gastric Cancer\nEstimated primary completion: 1 May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study 
 of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressi
 ng Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0437
 9596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study 
 of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressi
 ng Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0437
 9596
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study o
 f the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressin
 g Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043795
 96
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06213519-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:S-1: Phase 2 readout est. (NCT06213519)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: HIPEC Combined With SOX
  and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritonea
 l Metastasis\nEstimated primary completion: 30 May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06213519
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03421288-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03421288)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Study 
 of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Imm
 une Responsiveness\nEstimated primary completion: 31 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03421288
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669740-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT07669740)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study on the 
 Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel
  in the Treatment of Gastric Cancer Patients With Short-term Recurrence Af
 ter Adjuvant Therapy\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07669740
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532006-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06532006)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ Cl
 inical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for
  the Treatment of Gastroesophageal Junction and Gastric Cancer\nEstimated 
 primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06532006
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04396821-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04396821)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: A Trial to Eval
 uate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04396821
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03505320)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Zo
 lbetuximab (IMAB362) in Adults With Gastric Cancer\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03505320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03505320)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Zolbet
 uximab (IMAB362) in Adults With Gastric Cancer\nEstimated primary completi
 on: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03505320
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03505320)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Stud
 y of Zolbetuximab (IMAB362) in Adults With Gastric Cancer\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03505320
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05184803-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:S-1: Phase 2 readout est. (NCT05184803)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Phase 2 Study of Neoa
 djuvant Docetaxel\, Oxaliplatin\, S-1 in Patients With Unresectable Locall
 y Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05184803
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05184803-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05184803)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Phas
 e 2 Study of Neoadjuvant Docetaxel\, Oxaliplatin\, S-1 in Patients With Un
 resectable Locally Advanced or Distant Metastasis Limited to Lymph Node Ga
 stric Cancer\nEstimated primary completion: 30 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05184803
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068516-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07068516)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Perioperative 
 Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positiv
 e Gastric/GEJ Cancer\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07068516
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123494-9096@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06123494)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Gastric Cancer.\nStudy: SHR-A
 1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal J
 unction Adenocarcinoma After Progression on or After First-line Anti-HER2 
 Therapy-containing Regimen\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06123
 494
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025889-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:S-1: Phase 1/2 readout est. (NCT07025889)
DESCRIPTION:S-1\, phase 1/2\, Gastric Cancer.\nStudy: IBI343 Combined With 
 Sintilimab Plus Chemotherapy in Gastric Cancer\nEstimated primary completi
 on: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070258
 89
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025889-11359@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:TAK-921: Phase 1/2 readout est. (NCT07025889)
DESCRIPTION:TAK-921\, phase 1/2\, Gastric Cancer.\nStudy: IBI343 Combined W
 ith Sintilimab Plus Chemotherapy in Gastric Cancer\nEstimated primary comp
 letion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 k-921#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07025889
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294664-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07294664)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: PDL1/TGFβ
  In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line
  Treatment Of Gastric Cancer\nEstimated primary completion: 15 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07294664
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:S-1: Phase 3 readout est. (NCT04997837)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuvant Chemo
 therapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected 
 pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completion: 21 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04997837
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04997837)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuv
 ant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in 
 Resected pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completi
 on: 21 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04997837
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149090-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07149090)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: Lenvatinib in C
 ombination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer P
 atients With Malignant Ascites\nEstimated primary completion: 30 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07149090
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06116136-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06116136)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Gastric Cancer.\nStudy: A Study to 
 Evaluate the Safety and the Activity of S095029 as Part of Combination The
 rapy in Advanced Gastroesophageal Junction/Gastric Cancers.\nEstimated pri
 mary completion: August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06116136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06251973)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study of agen
 T-797 in Combination With Botensilimab\, Balstilimab\, Ramucirumab\, and P
 aclitaxel for People With Esophageal\, Gastric\, or Gastro-esophageal Junc
 tion Cancer\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-3287@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:agenT-797: Phase 2 readout est. (NCT06251973)
DESCRIPTION:agenT-797\, phase 2\, Gastric Cancer.\nStudy: A Study of agenT-
 797 in Combination With Botensilimab\, Balstilimab\, Ramucirumab\, and Pac
 litaxel for People With Esophageal\, Gastric\, or Gastro-esophageal Juncti
 on Cancer\nEstimated primary completion: 1 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/agent-797#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/agent-797#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531291-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06531291)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Surufatinib Com
 bined With Serplulimab and Standard Chemotherapy as First-line Treatment i
 n Advanced Solid Tumors With Neuroendocrine Differentiation\nEstimated pri
 mary completion: 9 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06531291
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04069273-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270811
DTEND;VALUE=DATE:20270812
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04069273)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Novel SEQUEnc
 ed Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastr
 oesophageaL Adenocarcinoma\nEstimated primary completion: 11 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04069273
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04069273-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270811
DTEND;VALUE=DATE:20270812
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT04069273)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: Novel SEQUEnced
  Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroe
 sophageaL Adenocarcinoma\nEstimated primary completion: 11 August 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04069273
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872696-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07872696)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Exploring the E
 fficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and
  SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Coho
 rt Study\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07872696
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253611-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06253611)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: First-line EXL01 
 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06253611
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Disitamab Vedo
 tin Combined With Tislelizumab and Capecitabine in the Perioperative Treat
 ment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEstimate
 d primary completion: 1 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative 
 Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEst
 imated primary completion: 1 September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Disitamab Vedo
 tin Combined With Tislelizumab and Capecitabine in the Perioperative Treat
 ment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEstimate
 d primary completion: 1 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Rilvegostomig\, phase 2\, Biliary Tract Cancer.\nStudy: Study o
 f Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Pa
 tients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Study of Da
 to-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patien
 ts With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary com
 pletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05489211
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06038578-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06038578)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: A Study of TRK-
 950 When Used in Combination With Ramucirumab and Paclitaxel in Patients W
 ith Gastric Cancer\nEstimated primary completion: 31 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06038578
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Nivolumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivoluma
 b to Usual Treatment for People With Advanced Stomach or Esophageal Cancer
 \, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Ramucirumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivolu
 mab to Usual Treatment for People With Advanced Stomach or Esophageal Canc
 er\, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06123338)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Pe
 mbrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastr
 ic Cancer\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Novel Combina
 tions in Participants With Locally Advanced Unresectable or Metastatic Gas
 tric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05702229
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06123338)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Stud
 y of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esopha
 gogastric Cancer\nEstimated primary completion: 30 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Novel Combinat
 ions in Participants With Locally Advanced Unresectable or Metastatic Gast
 ric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary complet
 ion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05702229
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06123338)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: A Study of Pem
 brolizumab With Trastuzumab and Chemotherapy in People With Esophagogastri
 c Cancer\nEstimated primary completion: 30 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-11152@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sonesitatug vedotin: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Sonesitatug vedotin\, phase 2\, Gastric Cancer.\nStudy: Novel C
 ombinations in Participants With Locally Advanced Unresectable or Metastat
 ic Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05702229
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Stu
 dy of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 E
 xpression Gastric Cancer\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Safety and
  Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or
  Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retli
 rafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07102901
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study o
 f the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expre
 ssion Gastric Cancer\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-9096@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Ph1b/
 2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced H
 ER2 Expression Gastric Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5671822
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-9096@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Safet
 y and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastr
 ic or Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07102901
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-11072@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07102901)
DESCRIPTION:SHR-A1904\, phase 2\, Gastric Cancer.\nStudy: Safety and Effica
 cy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro
 -oesophageal Junction Adenocarcinoma\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071029
 01
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438420-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438420)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: Oral Axl/M
 er/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pemb
 rolizumab in Patients With Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05438420
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018063-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:S-1: Phase 2 readout est. (NCT07018063)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Neoadjuvant Nab-Paclita
 xel Plus Oxaliplatin\, S-1\, and Sintilimab in Early-Onset Resectable Gast
 ric Cancer\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07018063
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933471-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07933471)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Total Neoadjuva
 nt Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroe
 sophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 3471
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927857-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT05927857)
DESCRIPTION:Ramucirumab\, phase 1/2\, Gastric Cancer.\nStudy: Ramucirumab (
 Cyramza)\, Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Secon
 d Line Metastatic Gastric Cancer .\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramucirumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 27857
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732856-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 1/2 readout est. (NCT06732856)
DESCRIPTION:S-1\, phase 1/2\, Gastric Cancer.\nStudy: A Phase Ib/II Trial o
 f Neoadjuvant Zolbetuximab Plus Docetaxel\, Oxaliplatin and S-1 Chemothera
 py in Patients With Locally Advanced Gastric Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06732856
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732856-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06732856)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Gastric Cancer.\nStudy: A Ph
 ase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel\, Oxaliplatin a
 nd S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06732856
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764251-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06764251)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab C
 ombined with SOX Regimen in the Treatment of Locally Advanced Gastric Canc
 er/gastroesophageal Junction Adenocarcinoma\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06764251
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943533-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07943533)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HLX22 Combinati
 on Therapy in HER2-Positive Limited Metastatic Gastric Cancer\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07943533
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374250-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 2 readout est. (NCT07374250)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Perioperative Ivonescim
 ab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Aden
 ocarcinoma\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07374250
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04840264-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04840264)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Doceta
 xel\, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bo
 wel Obstruction\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04840264
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311408-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07311408)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 +
  Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy F
 ailure\nEstimated primary completion: 1 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07311408
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109467-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06109467)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Neratinib In 
 Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesop
 hageal Cancer\nEstimated primary completion: March 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06109467
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938021-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07938021)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HLX22 Plus Serp
 lulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestina
 l Cancers\nEstimated primary completion: 1 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07938021
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06871527-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06871527)
DESCRIPTION:Tislelizumab\, phase 1/2\, Gastric Cancer.\nStudy: Fruquintinib
  Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advan
 ced Gastric Cancer\nEstimated primary completion: 30 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06871527
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542262-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07542262)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Low-dose Immun
 otherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMM
 R Cancers\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07542262
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04248452-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04248452)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Testing the Ad
 dition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients 
 With Esophageal and Gastric Cancer That Has Spread to a Limited Number of 
 Other Places in the Body\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04248452
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:S-1: Phase 2 readout est. (NCT07515625)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Efficacy of Sintilimab 
 Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-posi
 tive Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07515625
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07515625)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Efficacy of Si
 ntilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable
  AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated 
 primary completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07515625
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793917-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06793917)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Tislelizumab P
 lus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter\
 , Open-label\, Randomized Phase III Studyunresectable or Metastatic Gastri
 c/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 
 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06793917
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507526-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07507526)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: A Study o
 f Disitamab Vedotin\, Tunlametinib\, and PD-1 Antibody for Advanced Gastri
 c Cancer\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07507526
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07556640-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 2 readout est. (NCT07556640)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: LM-302 and S-1 Plus Int
 raperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-posit
 ive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Me
 tastasis: a Prospective\, Exploratory Study\nEstimated primary completion:
  30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07556
 640
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07621484)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming F
 ollowed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\n
 Estimated primary completion: 9 May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07621484
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:S-1: Phase 2 readout est. (NCT07621484)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming Followed 
 by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\nEstimate
 d primary completion: 9 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07621484
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07621484)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming 
 Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\
 nEstimated primary completion: 9 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07621484
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464756-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07464756)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 W
 ith or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Th
 erapy for Gastric Cancer\nEstimated primary completion: 31 May 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07464756
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464756-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:S-1: Phase 2 readout est. (NCT07464756)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 With or Withou
 t Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gas
 tric Cancer\nEstimated primary completion: 31 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07464756
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Co
 mbined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positi
 ve (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoc
 arcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076857
 04
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2201@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Zanidatamab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Com
 bined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positiv
 e (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoca
 rcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07685704
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:S-1: Phase 2 readout est. (NCT07685704)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Combined Wi
 th Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3
 + or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma:
  a Phase II Open-Label Study\nEstimated primary completion: June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07685704
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490990-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07490990)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Pos
 itive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prosp
 ective\, Single-Arm Phase II Clinical Trial\nEstimated primary completion:
  June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab
 -vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07490990
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Co
 mbined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positi
 ve (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoc
 arcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076857
 04
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731478-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06731478)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: Study of TDXd
 \, Chemotherapy\, Pembrolizumab\, and Trastuzumab in First-Line Metastatic
  HER2-Positive Gastric or Gastroesophageal Junction Cancer\nEstimated prim
 ary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06731478
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998771-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06998771)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: JSKN003 Combin
 ed Treatment of HER2-positive Gastric Cancer\nEstimated primary completion
 : 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06998771
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01935778-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT01935778)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Gastric Cancer.\nStudy: Compar
 e Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capeci
 tabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST
 15-08): TRIUMPH\nEstimated primary completion: 30 June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT01935778
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01935778-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 3 readout est. (NCT01935778)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Compare Adjuva
 nt Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/O
 xaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): 
 TRIUMPH\nEstimated primary completion: 30 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01935778
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655661-2010@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07655661)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Mannatide Comb
 ined With CAPOX and Tislelizumab for Advanced Gastric Cancer.\nEstimated p
 rimary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07655661
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655661-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07655661)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Mannatide Comb
 ined With CAPOX and Tislelizumab for Advanced Gastric Cancer.\nEstimated p
 rimary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07655661
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689851-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07689851)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Chemoradio
 therapy and SHR-1701 in Patients With Unresectable Gastric Cancer\nEstimat
 ed primary completion: 30 July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07689851
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194005-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:S-1: Phase 2 readout est. (NCT07194005)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Conversion Therapy With
  RC48\, Sintilimab\, and SOX for HER2 1+/2+ Unresectable Gastric Cancer\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07194005
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194005-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07194005)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Conversio
 n Therapy With RC48\, Sintilimab\, and SOX for HER2 1+/2+ Unresectable Gas
 tric Cancer\nEstimated primary completion: 30 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07194005
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Perioperative
  Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimated prim
 ary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Perioperative 
 Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimated prima
 ry completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-11152@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Sonesitatug vedotin: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Sonesitatug vedotin\, phase 2\, Gastric Cancer.\nStudy: Periope
 rative Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimate
 d primary completion: 30 October 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366528-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:S-1: Phase 3 readout est. (NCT07366528)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Adjuvant Oxaliplatin Pl
 us S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer\nEstimated p
 rimary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07366528
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05677490-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05677490)
DESCRIPTION:Nivolumab\, phase 3\, Gastric Cancer.\nStudy: mFOLFIRINOX Versu
 s mFOLFOX With or Without Nivolumab for the Treatment of Advanced\, Unrese
 ctable\, or Metastatic HER2 Negative Esophageal\, Gastroesophageal Junctio
 n\, and Gastric Adenocarcinoma\nEstimated primary completion: 8 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05677490
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Retlirafus
 p Alfa Combined With Zeprumetostat\, Apatinib\, and Chemotherapy as First-
 Line Treatment for Metastatic GC/GEJC\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp
 -alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07874425
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Retlirafusp Al
 fa Combined With Zeprumetostat\, Apatinib\, and Chemotherapy as First-Line
  Treatment for Metastatic GC/GEJC\nEstimated primary completion: December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078744
 25
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474324-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07474324)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy fo
 r HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective\, 
 Multicenter\, Randomized\, Phase Ⅱ Clinical Trial\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07474324
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677293-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 3 readout est. (NCT07677293)
DESCRIPTION:Retlirafusp alfa\, phase 3\, Gastric Cancer.\nStudy: Retlirafus
 p Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD
 -1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric
  Cancer With Liver Metastases\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 77293
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677293-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07677293)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Retlirafusp Al
 fa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 A
 ntibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Can
 cer With Liver Metastases\nEstimated primary completion: 31 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07677293
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492615-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:S-1: Phase 2 readout est. (NCT07492615)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Clinical Study of Sin
 tilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy 
 for Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary co
 mpletion: 20 February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07492615
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262619-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07262619)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: EIK1005-
 002: A Clinical Research Study Evaluating EIK1005\, a Werner Helicase Inhi
 bitor\, as Monotherapy and in Combination With Pembrolizumab in Participan
 ts With Advanced Solid Tumors Including Microsatellite Instability High (M
 SI-H) Tumors\nEstimated primary completion: March 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07262619
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176312-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07176312)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab i
 n Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positi
 ve Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients\nEstimated pr
 imary completion: March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07176312
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176312-2201@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07176312)
DESCRIPTION:Zanidatamab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab in 
 Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive
  Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients\nEstimated prim
 ary completion: March 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07176312
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313567-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290310
DTEND;VALUE=DATE:20290311
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06313567)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Metronomic Cap
 ecitabine in Stage III Gastric Cancer\nEstimated primary completion: 10 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 313567
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06005493-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290316
DTEND;VALUE=DATE:20290317
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06005493)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Gastric Cancer.\nStudy: Study of AZ
 D5863 in Adult Participants With Advanced or Metastatic Solid Tumors\nEsti
 mated primary completion: 16 March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06005493
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007182-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:S-1: Phase 2 readout est. (NCT07007182)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Conversion Therapy Plus
  Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric 
 Cancer\nEstimated primary completion: 1 April 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07007182
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007182-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07007182)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Conversion The
 rapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in
  Gastric Cancer\nEstimated primary completion: 1 April 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07007182
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ S
 tudy of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab
  Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer\n
 Estimated primary completion: 27 April 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ St
 udy of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab 
 Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer\nE
 stimated primary completion: 27 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2454@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: A Study o
 f Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated
  primary completion: 28 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06157892
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Establishm
 ent of Precision Targeted Therapy Strategies for Advanced Gastric Cancer B
 ased on Novel Molecular Subtyping\nEstimated primary completion: 1 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alf
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 881017
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:S-1: Phase 2 readout est. (NCT06881017)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Establishment of Precis
 ion Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel
  Molecular Subtyping\nEstimated primary completion: 1 August 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Establishment 
 of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based
  on Novel Molecular Subtyping\nEstimated primary completion: 1 August 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-9096@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Estab
 lishment of Precision Targeted Therapy Strategies for Advanced Gastric Can
 cer Based on Novel Molecular Subtyping\nEstimated primary completion: 1 Au
 gust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06881017
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-11072@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT06881017)
DESCRIPTION:SHR-A1904\, phase 2\, Gastric Cancer.\nStudy: Establishment of 
 Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on
  Novel Molecular Subtyping\nEstimated primary completion: 1 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1904#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Nivolumab\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug Vedot
 in in Combination With Capecitabine With or Without Rilvegostomig in Parti
 cipants With Advanced or Metastatic Gastric\, Gastroesophageal Junction\, 
 or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary com
 pletion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07431281
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug V
 edotin in Combination With Capecitabine With or Without Rilvegostomig in P
 articipants With Advanced or Metastatic Gastric\, Gastroesophageal Junctio
 n\, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary
  completion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug Ve
 dotin in Combination With Capecitabine With or Without Rilvegostomig in Pa
 rticipants With Advanced or Metastatic Gastric\, Gastroesophageal Junction
 \, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary 
 completion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-11152@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Sonesitatug vedotin: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Sonesitatug vedotin\, phase 3\, Gastric Cancer.\nStudy: Sonesit
 atug Vedotin in Combination With Capecitabine With or Without Rilvegostomi
 g in Participants With Advanced or Metastatic Gastric\, Gastroesophageal J
 unction\, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated p
 rimary completion: 16 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03228667)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who 
 Have Previously Received Treatment With Immune Checkpoint Inhibitors\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818018-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290904
DTEND;VALUE=DATE:20290905
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07818018)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: A Study of 2141
 -V11 in People With Esophageal\, Gastric\, or Gastroesophageal Junction Ad
 enocarcinoma\nEstimated primary completion: 4 September 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07818018
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093425-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06093425)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: Combination o
 f Osemitamab (TST001)\, Pembrolizumab and Chemotherapy as First-line Thera
 py in Advanced or Metastatic GC/GEJ Adenocarcinoma\nEstimated primary comp
 letion: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06093425
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115043-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety of AZD6750 in Adult Participants With Selec
 t Advanced or Metastatic Solid Tumors\nEstimated primary completion: 2 Oct
 ober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegosto
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07115043
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522151-2242@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:S-1: Phase 3 readout est. (NCT07522151)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Clinical Study of Adebr
 elimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroe
 sophageal Junction Cancer\nEstimated primary completion: December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07522151
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904442-2061@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07904442)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Applicatio
 n of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric
  Cancer With Peritoneal Metastasis\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp
 -alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07904442
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507916-2161@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07507916)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Dynamic ctDNA-G
 uided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal J
 unction Adenocarcinoma\nEstimated primary completion: 31 December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07507916
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962137-2013@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06962137)
DESCRIPTION:Ramucirumab\, phase 2\, Gastric Cancer.\nStudy: Phase II RAINSP
 OT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esoph
 ageal Cancer\nEstimated primary completion: 31 December 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06962137
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07432295)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combin
 ed With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metast
 atic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07432295)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Givastomig Com
 bined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Met
 astatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-10902@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:givastomig: Phase 2 readout est. (NCT07432295)
DESCRIPTION:givastomig\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combi
 ned With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metas
 tatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/givastomig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/givastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872722-9029@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07872722)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Zolbet
 uximab\, Durvalumab\, and FLOT Combination Neoadjuvant Chemotherapy for CL
 DN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 31 March 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07872722
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788664-1986@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07788664)
DESCRIPTION:Rilvegostomig\, phase 2\, Gastric Cancer.\nStudy: Local and Sys
 temic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Adv
 anced Gastric Cancer (RILVE Project)\nEstimated primary completion: 1 June
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0778
 8664
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818070-2656@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:ONO-4578: Phase 3 readout est. (NCT07818070)
DESCRIPTION:ONO-4578\, phase 3\, Gastric Cancer.\nStudy: A Trial of ONO-457
 8 Versus Placebo in Combination With Nivolumab and Chemotherapy in Partici
 pants With Gastric Cancer\, Esophagogastric Junction Cancer\, or Esophagea
 l Adenocarcinoma\nEstimated primary completion: January 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ono-4578#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07818070
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673887-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07673887)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: A Study of AS
 P2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric 
 Cancer\nEstimated primary completion: 28 February 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07673887
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673887-11060@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:ASP2138: Phase 3 readout est. (NCT07673887)
DESCRIPTION:ASP2138\, phase 3\, Gastric Cancer.\nStudy: A Study of ASP2138 
 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
 \nEstimated primary completion: 28 February 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/asp2138#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07673887
URL:https://assetmemo.bio/drug/asp2138#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438459-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438459)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Gastric Cancer.\nStudy: GAIA-102 In
 traperitoneal Administration in Patients With Advanced Gastrointestinal Ca
 ncer of Microsatellite Stable With Malignant Ascites\nEstimated primary co
 mpletion: 31 March 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05438459
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332533-9047@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07332533)
DESCRIPTION:Capecitabine\, phase 2/3\, Gastric Cancer.\nStudy: A Study of K
 N026-based Combination Therapy in HER2-positive Gastric Cancer\nEstimated 
 primary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07332533
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1973@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 oncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiat
 ion Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary co
 mpletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1974@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Concu
 rrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation 
 Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary comple
 tion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07770100
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
